Advertisement
Home »

Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.

May 01, 2023

ABOUT THE CONTRIBUTORS

  • Xiaoyi Du

    Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

    Zhipeng Zhao

    Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

    Xin Zhao

    Department of Urology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

    Hexi Wang

    Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

    Li Jiang

    Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: 204215@hospital.cqmu.edu.cn.

    Wei Tang

    Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: 201522@hospital.cqmu.edu.cn.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement